Clinical Trial Update: A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

View source ↗

Summary

This clinical trial update discusses neuropathy associated with enfortumab vedotin in people with urothelial carcinoma, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Padcev (enfortumab vedotin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuropathy, Urothelial Carcinoma | Status: RECRUITING